• In recent weeks, Becton, Dickinson and Company has highlighted new clinical data for its PureWick Urine Collection System, launched the HemoSphere Stream Module for continuous noninvasive blood pressure monitoring, advanced its Liverty TIPS Stent Graft program in portal hypertension, and received multi-category supply chain resilience awards from the Healthcare Industry Resilience Collaborative.
• Taken together, these developments underline BD’s push into higher-value, clinically differentiated devices while reinforcing its reputation as a reliable, resilient partner for health systems.
• We’ll now examine how BD’s progress with technologies like PureWick could influence the company’s broader investment narrative and long-term positioning.

Uncover the next big thing with 26 elite penny stocks that balance risk and reward.

Becton Dickinson Investment Narrative Recap

To own BD, you need to believe in a resilient, consumables-heavy medtech franchise that can keep growing earnings while managing tariffs, China pricing pressure, and the Biosciences/Diagnostics separation. The latest product news in PureWick, Liverty TIPS, and HemoSphere supports the thesis around higher-value innovation, but it does not fundamentally shift the near term focus on executing the spin and containing margin drag from trade and procurement headwinds.

Among the recent updates, the new clinical data on the PureWick Urine Collection System stands out, because it ties directly into BD’s push toward home-based care and differentiated consumables. If PureWick adoption strengthens over time, it could become a meaningful contributor to the company’s recurring revenue mix, which is an important backdrop for how investors think about both the benefits and execution risks of the planned Biosciences/Diagnostics separation.

Yet even with this innovation push, investors should be aware that the planned Biosciences and Diagnostics separation could still...

Becton Dickinson's narrative projects $20.8 billion revenue and $2.2 billion earnings by 2029. This implies a 1.8% yearly revenue decline and about a $0.4 billion earnings increase from $1.8 billion today.

Uncover how Becton Dickinson's forecasts yield a $192.31 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were assuming BD could reach about US$25.0 billion in revenue and US$3.3 billion in earnings by 2028, so when you compare that to concerns about rising competition and digital health shifts, it shows just how far views can diverge and why these new PureWick and interventional launches may cause both the bullish and cautious narratives to evolve from here.

Explore 2 other fair value estimates on Becton Dickinson - why the stock might be worth as much as 36% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Becton Dickinson research is our analysis highlighting 6 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Becton Dickinson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Becton Dickinson's overall financial health at a glance.

Ready For A Different Approach?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 31 companies in the world exploring or producing it. Find the list for free.
• This technology could replace computers: discover 25 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.